-
Endo Pharmaceuticals Inc. et al v. Actavis LLC, et al. DC CAFC
- 1:14-cv-01381
- D. Del.
- Filed: 11/07/2014
- Closed: 06/21/2019
- Latest Docket Entry: 10/14/2020
- Judge: Richard G. Andrews
- PACER
2
Plaintiffs
7
Defendants
1
Accused
Product
2
Patents-in-Suit
1,688
Days in
Litigation
-
Endo Pharmaceuticals Inc. et al v. Actavis LLC, et al. DC CAFC
- 1:14-cv-01381
- D. Del.
- Filed: 11/07/2014
- Closed: 06/21/2019
- Latest Docket Entry: 10/14/2020
- Judge: Richard G. Andrews
- PACER
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
| Claim | Outcome |
|---|---|
| All challenged claims |
Invalid (101)
Entry 190 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A hydrochloride salt of oxymorphone comprising less than 0.001% of 14-hydroxymorphinone.
|
Valid (112)
Entry 246 Entry 232 |
| 2 |
The hydrochloride salt of claim 1 comprising less than 0.0005% of 14-hydroxymorphinone.
|
Valid (112)
Entry 246 Entry 232 |
| 3 |
A pharmaceutical acceptable form comprising the oxymorphone hydrochloride according to claim 1.
|
Valid (112)
Entry 246 Entry 232 |
| 4 |
A hydrochloride salt of a morphinan-6-one compound corresponding to Formula (2): <chemistry id="CHEM-US-00026" num="00026"><img id="EMI-C00026" he="38.52mm" wi="54.10mm" file="US08871779-20141028-C00026.TIF" alt="embedded image" img-content="chem"
view more
|
Valid (112)
Entry 246 Entry 232 |
| 5 |
The hydrochloride salt of claim 4 comprising less than 0.0005% of 14-hydroxymorphinone.
|
Valid (112)
Entry 246 Entry 232 |
| 6 |
A pharmaceutical formulation comprising the oxymorphone hydrochloride according to claim 4.
|
Valid (112)
Entry 246 Entry 232 |
-
Infringement
Actavis Incorporated
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| oxymorphone hydrochloride extended-release tablets | US 8,871,779 B2 |
1, 2, 3, 4, 5, 6
|
No infringement
Entry 246
|
Actavis LLC
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg of Oxymorphone ER Tablets | US 8,808,737 B2 | All Asserted Claims |
No infringement
Entry 190
|
Actavis South Atlantic LLC
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg of Oxymorphone ER Tablets | US 8,808,737 B2 | All Asserted Claims |
No infringement
Entry 190
|
| oxymorphone hydrochloride extended-release tablets | US 8,871,779 B2 |
1, 2, 3, 4, 5, 6
|
No infringement
Entry 246
|
Teva Pharmaceutical Europe BV
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| oxymorphone hydrochloride extended-release tablets | US 8,871,779 B2 |
1, 2, 3, 4, 5, 6
|
No infringement
Entry 246
|
Teva Pharmaceuticals USA, Inc.
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg of Oxymorphone ER Tablets | US 8,808,737 B2 | All Asserted Claims |
No infringement
Entry 190
|